Clover Corporation Posts $86 Million in FY25 Sales with Strong Second-Half Surge

Clover Corporation delivered a robust FY25 with strong second-half sales and operational milestones, positioning itself for continued growth in FY26 amid ongoing innovation and market expansion.

  • Second-half FY25 sales surged to $48.4 million, driven by Human Nutrition demand
  • Successful commissioning of fish oil extraction facility in Ecuador
  • Melody Dairies achieved first full-year profit
  • Debt reduction supported by improved margins and cost discipline
  • Innovation projects like CholineXcel and Premneo advancing with regulatory progress
An image related to Clover Corporation Limited A photo of the logo for Clover Add us as a preferred source on Google
Image © middle. Logo © respective owner.

A Tale of Two Halves

Clover Corporation’s fiscal year 2025 unfolded as a story of resilience and strategic execution. The company experienced steady demand in the first half, generating $37.6 million in revenue, before a pronounced uplift in the second half pushed sales to $48.4 million. This surge was largely fueled by increased orders from Human Nutrition customers, culminating in a record final quarter where $4 million in orders were brought forward to meet new product launch demand.

Operational Milestones and Margin Gains

Operationally, Clover marked significant progress. The commissioning of its fish oil extraction facility in Ecuador proved successful, delivering high-quality crude oil and securing supply chain advantages. While throughput improvements remain a target, the facility already contributes to cost and yield benefits that enhance gross margins.

Meanwhile, Melody Dairies celebrated its first full year of profitability, a milestone achieved through improved planning, longer production runs, and consistent equipment uptime. Although operating near capacity, the facility is expected to drive further efficiency and margin improvements as its product mix evolves.

At the Melbourne refinery, steady performance continues to underpin Clover’s vertically integrated supply chain. While margin gains here are incremental, the refinery remains a critical asset in ensuring product quality and supply consistency.

Innovation and Market Expansion

Clover’s innovation pipeline is advancing with promising projects. The CholineXcel powder, targeting infant formula and prenatal nutrition markets, is progressing through patent applications and customer trials. Anticipating demand, Clover is exploring options to expand drying capacity, including joint ventures or acquisitions.

Other products, such as encapsulated powders and Gelphorm, are in earlier stages but hold medium-term growth potential in high-value nutraceutical markets. Regulatory approval efforts for Premneo in Australia, New Zealand, and Europe are underway, with trial results under expert review, a critical step toward market entry.

The company’s new distributor model is expanding its footprint across North America, Asia, and Europe. FY26 will be pivotal in demonstrating the model’s benefits through sales growth, new product launches, and diversification across customers and markets.

Outlook and Strategic Focus

After a record FY25 final quarter, Clover experienced a slower start to FY26 but reports that trading is now showing steady growth and order flow. The company expects first-half FY26 revenues to surpass the prior year, reflecting confidence in its growth trajectory.

Cost management, particularly around energy inputs, remains a focus as Clover scales manufacturing and prepares for expansion. The combination of operational discipline, innovation, and market development positions Clover well to continue reducing debt and enhancing shareholder value.

Get ASX:CLV news the moment it breaks

Instant push notifications No waitlist Free
Download on the App Store iPhone & iPad
Get it on Google Play Android
Email alerts

Bottom Line?

Clover’s FY25 momentum and innovation pipeline set a promising stage, but FY26 execution will be critical to sustain growth and realise new product potential.

Questions in the middle?

  • How quickly can Clover scale production capacity to meet anticipated demand for CholineXcel?
  • What impact will regulatory approvals for Premneo have on Clover’s market access and revenue streams?
  • How effective will the new distributor model be in driving sustainable sales growth across diverse regions?